← Eichor
Study identifier: NCT03143374 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

PET Tau - Neurodegenerative Disease Imaging

Condition: Neurodegenerative Disease  ·  Sponsor: University of Pennsylvania

PhasePhase 2/Phase 3
Planned participants300
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersYes

About this study

The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such as frontotemporal degeneration (FTD).

This description comes directly from the study's public registry record.

Talk to the study team

Dahlia Kamel  ·  215-662-6134  ·  kamel.dahlia@pennmedicine.upenn.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of PennsylvaniaPhiladelphia, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03143374